Picture Demy-Colton BioFuture 2021 NYC C Virtual Option 650x80px
Organisation › Details

Alexion (Group)

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercialises two approved complement inhibitors to treat patients with PNH and atypical haemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalised myasthenia gravis and neuromyelitis optica spectrum disorder. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, Alexion is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, FcRn antibody for rare IgG-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. During 2019, Alexion generated a total revenue of $5bn and profit before tax of $2.2bn. As of 30 September 2020, Alexion had gross assets of $17.5bn. Alexion's executive officers are Ludwig Hantson (Chief Executive Officer), Aradhana Sarin (Chief Financial Officer), Tanisha Carino (Chief Corporate Affairs Officer), Ellen Chiniara (Chief Legal Officer and Corporate Secretary), Indrani Franchini (Chief Compliance Officer), Brian Goff (Chief Commercial and Global Operations Officer), and John Orloff (Head of Research and Development). *


Period Start 1992-01-31 established
Products Industry pharmaceutical
  Industry 2 DRUGS, ORPHAN
  Street 352 Knotter Dr.
  City 06410 Cheshire, CT
  Tel +1-203-272-2596
    Address record changed: 2020-12-02
Basic data Employees n. a.
  Currency USD
  Annual sales 200,000 (revenues, total, consolidated (2006) 2006-12-31)
  Profit -39,300,000 (2006-12-31)
  Cash 250,148,000 (2006-12-31)
    * Document for �About Section�: AstraZeneca plc. (12/12/20). "Press Release: AstraZeneca to Acquire Alexion, Accelerating the Company’s Strategic and Financial Development [Not for any jurisdicition where violation of relevant laws]".
Record changed: 2020-12-13


Picture [iito] Made Without Love 650x80px

More documents for Alexion (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top